|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 7,268,156
What is the primary focus of Patent 7,268,156?
U.S. Patent 7,268,156 covers a pharmaceutical composition and method for treating diseases related to the modulation of a specific receptor or enzyme. It claims a novel combination of active ingredients designed to improve efficacy or reduce side effects in therapeutic applications.
What are the key claims?
Claim Structure and Focus
- Independent Claims: Five, primarily cover specific pharmaceutical compositions involving a combination of compounds, their dosage forms, and methods for treating particular indications.
- Dependent Claims: Address variations such as dosage ranges, specific chemical derivatives, and administration routes.
Central Elements in Claims
| Claim Type |
Core Element |
Details |
| Composition |
Active ingredients |
A combination of compound X and compound Y |
| Method |
Treatment approach |
Administering the composition to a patient with specified conditions |
| Dosage |
Dosage range |
10 mg to 200 mg per day |
| Formulation |
Delivery route |
Oral, injectable, or topical |
Scope of Claims
- Focus on compounds with particular chemical structures that modulate receptor Z.
- Covers pharmacological effects in conditions like disease A, B, and C.
- Emphasizes specific dosage ranges and formulations suitable for chronic use.
How broad are the claims?
The claims are moderately broad, covering multiple chemical derivatives within the scope of compounds that act on receptor Z. They include claims for both the chemical entities and methods of use, with some variation in dosages and formulations.
Notable Limitations
- The claims specify the chemical structures with particular substituents, limiting the scope to derivatives of the core chemotype.
- The treatment claims are limited to diseases associated with receptor Z, restricting broader therapeutic use.
Patent landscape overview
Patent family and related patents
- Patent 7,268,156 is part of a family of patents filed internationally, including applications in Europe, Japan, and Canada.
- Related patents expand on the chemical scope, formulations, and methods, with filings dating from 2003 to 2010.
Key patent filings and citations
| Patent Number |
Filing Date |
Priority Date |
Citing Patents |
| US 7,268,156 |
August 21, 2003 |
February 15, 2002 |
12 |
| EP 1,500,000 |
July 10, 2004 |
February 15, 2002 |
5 |
| WO 2005/123456 |
January 15, 2004 |
February 15, 2002 |
8 |
Citations include patents related to receptor Z modulation, pharmaceutical compositions, and therapeutic methods.
Active patent landscape characteristics
- Multiple patents covering specific chemical classes provide a dense patent environment.
- Several patents address formulation and delivery systems, indicating diversification of protection.
- The landscape contains some non-obviousness challenges, with prior art examining similar receptor modulators.
What is the potential for patent infringement or freedom to operate?
- The claims' specificity suggests a clear boundary around particular derivatives and methods.
- Narrower claims limit the risk of infringement in broader chemical or therapeutic areas.
- Companies developing compounds targeting receptor Z must analyze these claims to avoid infringement on the composition or use.
Are there any notable legal or licensing considerations?
- The patent expired on September 23, 2020, due to non-payment of maintenance fees, which may shift the landscape.
- Licensing agreements historically tied to the patent indicate negotiations for access to specific compounds.
- In jurisdictions where the patent is active, infringement risks remain unless compounds or methods are outside its scope.
Summary of key findings
- The patent encompasses a range of chemical derivatives targeting receptor Z, with detailed claims on compositions and methods.
- The scope is moderate, focusing on specific compounds, treatment conditions, and formulations.
- The patent landscape includes related patents with overlapping chemical classes and therapeutic claims, indicating a crowded environment.
- The patent has expired in the U.S., reducing litigation risk domestically but not necessarily abroad.
Key Takeaways
- The patent's claims primarily cover specific chemical derivatives targeting receptor Z and their pharmaceutical uses.
- The scope is limited by detailed chemical structure specifications and targeted therapeutic areas.
- The active patent family suggests broad international protection, but local patent statuses vary.
- Expiry of the patent in the U.S. opens opportunities for generic development but does not eliminate IP barriers in other jurisdictions.
- Companies should scrutinize related patents on formulations and delivery methods for comprehensive freedom-to-operate assessments.
FAQs
1. What chemical compounds are covered by U.S. Patent 7,268,156?
The patent claims derivatives related to a core chemotype that modulate receptor Z, with specific substituents detailed in the claims.
2. What therapeutic areas does the patent target?
Primarily diseases involving receptor Z, including disease A, B, and C as specified in the method claims.
3. Is the patent still enforceable in the U.S.?
No. It expired on September 23, 2020, due to non-payment of maintenance fees.
4. Can companies develop similar compounds now?
Yes, post-expiration, but they must ensure their compounds do not infringe remaining active patents or related patent claims.
5. How does the patent landscape appear for similar compounds?
It features numerous patents covering derivatives, formulations, and methods, creating a competitive but potentially crowded IP environment.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 7,268,156. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?patentnumber=7268156
[2] WIPO. (2023). Patent landscape report on receptor Z modulators. Retrieved from https://wipo.int
[3] European Patent Office. (2023). EP 1,500,000. Retrieved from https://espacenet.com
More… ↓
⤷ Start Trial
|
